The goal of this trial was to assess the feasibility and safety of using
S-adenosyl-L-methionine (SAMe) to treat
depressive disorder,
attention deficit/hyperactivity disorder (
ADHD) and cognitive deficits in individuals with the
22q11.2 deletion syndrome (
22q11.2DS). SAMe supposedly enhances the activity of the COMT
enzyme. Because individuals with
22q11.2DS have only one copy of the gene responsible for the
enzyme, COMT haploinsufficiency may be associated with their psychiatric morbidity and cognitive deficits. We assessed twelve
22q11.2DS individuals with
depressive disorder or
ADHD in a randomized double-blind cross-over placebo-controlled trial, using SAMe 800 mg bid. Individuals were evaluated for treatment safety and effectiveness during the trial and upon completion at sixth week. Compared to placebo, there were no significant differences in the rate of reported side effects between SAMe and placebo. Despite a general concern that SAMe might induce
mania in vulnerable individuals, no manic or psychotic symptoms were exhibited during the SAMe treatment. Individuals with
22q11.2DS with comorbid
depressive disorder with or without psychotic symptoms (n = 5) had a larger numerical improvement on relevant clinical scales compared to placebo. No treatment effect was found on
ADHD symptoms in subjects who suffered from
22q11.2DS with comorbid
ADHD (n = 7). Cognitive performance did not improve or deteriorate following treatment with SAMe compared to placebo. In conclusion SAMe treatment up to 1,600 mg/day for 6 weeks in
22q11.2DS individuals appears to be safe, well tolerated and with no serious side effects. No significant benefit in depressive or
ADHD symptoms was detected.